Zhang, Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome
The move towards early combination therapy, especially with the inclusion of SGLT2 inhibitors and GLP-1 RAs, reflects the growing recognition of their cardiorenal benefits beyond glycemic control
Professor Moses Elisaf has received speaker honoraria, consulting fees, and research funding from AstraZeneca, Schering Plough, Merck, Pfizer, Solvay, Abbott, Boehringer Ingelheim, and Fournier, and has participated in clinical trials with AstraZeneca, Merck, Sanofi-Synthelabo, Solvay, Glaxo, Novartis, Pfizer, and Fournier
Compounded semaglutide: Contains the same active ingredient as both Ozempic and Wegovy, bypassing some of the brand-name coverage issues